ACE2类似酶B38-CAP调节新型冠状病毒肺炎患者RAS系统平衡的作用分析

The Role of B38-CAP,an ACE2-Like Enzyme,in Regulating RAS System in the COVID-19

截止2020年4月7日,全球累计报告感染新型冠状病毒肺炎患者1 259 440例,累计死亡71 108例,涉及123个国家,其中美国累计确诊337 971例,死亡9 654例,西班牙累计确诊135 032例,死亡12 055例。全球死亡比例高达5.65%。新型冠状病毒传染性强,目前尚无特效药。缓解患者临床症状、降低患者死亡率是重要的临床问题。西湖大学周强教授团队研究发现了新型冠状病毒S蛋白和ACE2受体的复合结构,发现新型冠状病毒通过S蛋白与人细胞受体ACE2结合。冠状病毒与ACE2受体结合后致ACE2减少、RAS系统激活进而致病。提高ACE2表达可能对缓解新型冠状病毒肺炎患者临床症状有一定疗效,但这是否会增加新型冠状病毒感染风险目前争议颇大。B38-CAP是一种ACE2类似酶,与ACE2作用类似,可水解Ang II,抑制RAS系统,保护肺和心血管系统。同时B38-CAP不与新型冠状病毒结合,不会增加新型冠状病毒感染风险。这可能为药物治疗新型冠状病毒肺炎提供新的思路。

The coronavirus disease 2019(COVID-19)has spread to 123 countries in the worldwide. As of the cutoff the 7 th of April,2020,about 1,259,440 people was infected with the novel coronavirus(SARS-CoV-2)in the worldwide. 71,108 patients have died of COVID-19. 337,971 people were infected with SARS-CoV-2 and 9,654 patients were died of this disease in America. In Spain,135,032 patients had been diagnosed and 12,055 patients were died. The mortality of COVID-19 is up to 5.65% in worldwide. Due to the strong infectiousness,COVID-19 has attracted all the attention of scientists all over the world. There is no specific medicine for treating COVID-19. Relieving symptoms and decreasing mortality are very important. The structure of combination between SARS-CoV-2 and ACE2 has been reported in the latest research. Associated with the reported researches about SARS-CoVs in the past,many scientists hold the hypothesis that decreased ACE2 and over-activated RAS system may be the pathogenesis of COVID-19. Increasing ACE2 expression may be advantage to this disease,but it is still controversial whether RAS inhibitor will increase the risk of SARS-CoV-2 infection. B38-CAP,a bacteria-derived ACE2-like enzyme,can cleaves Ang II to Ang 1–7 and inhibit RAS system. Different from ACE2,B38-CAP does not combine with SARS-CoV-2 and will not increase the risk of 2019-nCoV infection. B38-CAP may provide a new thought for SARS-CoV-2 treating.